ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/18/2023 | 11.8% | Citigroup | $2.1 → $1.8 | Maintains | Buy |
| 08/07/2023 | 210.56% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/04/2023 | 24.22% | Chardan Capital | → $2 | Reiterates | Neutral → Neutral |
| 05/17/2023 | 179.5% | Cantor Fitzgerald | $5 → $4.5 | Maintains | Overweight |
| 05/17/2023 | 272.67% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 05/17/2023 | 210.56% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 03/30/2023 | 272.67% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 03/30/2023 | 210.56% | HC Wainwright & Co. | $1.5 → $5 | Maintains | Buy |
| 12/23/2022 | 210.56% | Raymond James | $2 → $5 | Maintains | Outperform |
| 12/22/2022 | 210.56% | Cantor Fitzgerald | $0.8 → $5 | Upgrades | Neutral → Overweight |
| 08/15/2022 | -6.83% | HC Wainwright & Co. | $2 → $1.5 | Maintains | Buy |
| 08/12/2022 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 08/12/2022 | 24.22% | Raymond James | → $2 | Upgrades | Market Perform → Outperform |
| 05/09/2022 | 24.22% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 05/06/2022 | 24.22% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 04/14/2022 | 55.28% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 04/14/2022 | 210.56% | JMP Securities | $8 → $5 | Maintains | Market Outperform |
| 02/14/2022 | 396.89% | Chardan Capital | $18 → $8 | Maintains | Buy |
| 02/14/2022 | 396.89% | JMP Securities | $29 → $8 | Maintains | Market Outperform |
| 02/14/2022 | 148.45% | HC Wainwright & Co. | $20 → $4 | Maintains | Buy |
| 02/14/2022 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 02/01/2022 | 1080.12% | Raymond James | → $19 | Initiates Coverage On | → Strong Buy |
| 08/09/2021 | 1018.01% | Chardan Capital | $20 → $18 | Maintains | Buy |
| 05/03/2021 | 1142.24% | Stifel | → $20 | Initiates Coverage On | → Buy |
| 08/11/2020 | 1142.24% | Chardan Capital | $25 → $20 | Maintains | Buy |
| 11/19/2019 | 1949.69% | Citigroup | $40 → $33 | Maintains | Buy |
| 11/14/2018 | 2384.47% | Cantor Fitzgerald | → $40 | Initiates Coverage On | → Overweight |
| 09/19/2018 | 2073.91% | Evercore ISI Group | → $35 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/18/2023 | 11.8% | 花旗集团 | $2.1→$1.8 | 维护 | 买 |
| 08/07/2023 | 210.56% | HC Wainwright公司 | →$5 | 重申 | 购买→购买 |
| 08/04/2023 | 24.22% | 查尔丹资本 | →$2 | 重申 | 中性→中性 |
| 2023年05月17日 | 179.5% | 康托·菲茨杰拉德 | $5→$4.5 | 维护 | 超重 |
| 2023年05月17日 | 272.67% | JMP证券 | →$6 | 重申 | 市场表现优于→市场表现 |
| 2023年05月17日 | 210.56% | HC Wainwright公司 | →$5 | 重申 | 购买→购买 |
| 03/30/2023 | 272.67% | JMP证券 | →$6 | 重申 | →市场跑赢大盘 |
| 03/30/2023 | 210.56% | HC Wainwright公司 | $1.5→$5 | 维护 | 买 |
| 2022年12月23日 | 210.56% | 雷蒙德·詹姆斯 | $2→$5 | 维护 | 跑赢大盘 |
| 2022年12月22日 | 210.56% | 康托·菲茨杰拉德 | $0.8→$5 | 升级 | 中性→超重 |
| 2022年08月15日 | -6.83% | HC Wainwright公司 | $2→$1.5 | 维护 | 买 |
| 2022年08月12日 | - | 查尔丹资本 | 评级下调 | 购买→中性 | |
| 2022年08月12日 | 24.22% | 雷蒙德·詹姆斯 | →$2 | 升级 | 市场表现优于→ |
| 05/09/2022 | 24.22% | HC Wainwright公司 | $4→$2 | 维护 | 买 |
| 05/06/2022 | 24.22% | 查尔丹资本 | $2.5→$2 | 维护 | 买 |
| 04/14/2022 | 55.28% | 查尔丹资本 | $8→$2.5 | 维护 | 买 |
| 04/14/2022 | 210.56% | JMP证券 | $8→$5 | 维护 | 市场表现强于大盘 |
| 02/14/2022 | 396.89% | 查尔丹资本 | $18→$8 | 维护 | 买 |
| 02/14/2022 | 396.89% | JMP证券 | $29→$8 | 维护 | 市场表现强于大盘 |
| 02/14/2022 | 148.45% | HC Wainwright公司 | $20→$4 | 维护 | 买 |
| 02/14/2022 | - | 雷蒙德·詹姆斯 | 评级下调 | 强劲的购买→市场表现 | |
| 02/01/2022 | 1080.12% | 雷蒙德·詹姆斯 | →$19 | 开始承保 | →强势购买 |
| 08/09/2021 | 1018.01% | 查尔丹资本 | $20→$18 | 维护 | 买 |
| 05/03/2021 | 1142.24% | Stifel | →$20 | 开始承保 | →购买 |
| 2020年08月11日 | 1142.24% | 查尔丹资本 | $25→$20 | 维护 | 买 |
| 2019年11月19日 | 1949.69% | 花旗集团 | $40→$33 | 维护 | 买 |
| 2018年11月14日 | 2384.47% | 康托·菲茨杰拉德 | →$40 | 开始承保 | →超重 |
| 2018年09月19日 | 2073.91% | Evercore ISI集团 | →$35 | 开始承保 | →跑赢大盘 |
What is the target price for ProQR Therapeutics (PRQR)?
ProQR治疗(PRQR)的目标价格是多少？
The latest price target for ProQR Therapeutics (NASDAQ: PRQR) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $1.80 expecting PRQR to rise to within 12 months (a possible 11.80% upside). 10 analyst firms have reported ratings in the last year.
花旗集团于2023年9月18日报道了ProQR治疗公司(纳斯达克：PRQR)的最新目标价。这家分析公司将目标价定为1.80美元，预计PRQR将在12个月内升至(可能上涨11.80%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
ProQR治疗公司(PRQR)的最新分析师评级是什么？
The latest analyst rating for ProQR Therapeutics (NASDAQ: PRQR) was provided by Citigroup, and ProQR Therapeutics maintained their buy rating.
花旗集团提供了对ProQR治疗公司(纳斯达克代码：PRQR)的最新分析师评级，而ProQR治疗公司维持其买入评级。
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
ProQR治疗(PRQR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与ProQR治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。ProQR治疗公司的上一次评级是在2023年9月18日提交的，所以你应该预计下一次评级将在2024年9月18日左右提供。
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
分析师对ProQR Treeutics(PRQR)的评级正确吗？
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a maintained with a price target of $2.10 to $1.80. The current price ProQR Therapeutics (PRQR) is trading at is $1.61, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的ProQR治疗(PRQR)评级保持不变，目标价在2.10美元至1.80美元之间。ProQR治疗公司(PRQR)目前的交易价格为1.61美元，超出了分析师的预测范围。